245 related articles for article (PubMed ID: 23083346)
1. CD22 and autoimmune disease.
Dörner T; Shock A; Smith KG
Int Rev Immunol; 2012 Oct; 31(5):363-78. PubMed ID: 23083346
[TBL] [Abstract][Full Text] [Related]
2. Epratuzumab for systemic lupus erythematosus.
Wallace DJ; Goldenberg DM
Lupus; 2013 Apr; 22(4):400-5. PubMed ID: 23553783
[TBL] [Abstract][Full Text] [Related]
3. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
Dörner T; Shock A; Goldenberg DM; Lipsky PE
Autoimmun Rev; 2015 Dec; 14(12):1079-86. PubMed ID: 26212727
[TBL] [Abstract][Full Text] [Related]
4. CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation.
Sieger N; Fleischer SJ; Mei HE; Reiter K; Shock A; Burmester GR; Daridon C; Dörner T
Arthritis Rheum; 2013 Mar; 65(3):770-9. PubMed ID: 23233360
[TBL] [Abstract][Full Text] [Related]
5. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
[TBL] [Abstract][Full Text] [Related]
6. Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22.
Özgör L; Brandl C; Shock A; Nitschke L
Eur J Immunol; 2016 Sep; 46(9):2260-72. PubMed ID: 27352780
[TBL] [Abstract][Full Text] [Related]
7. Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
Chang CH; Wang Y; Gupta P; Goldenberg DM
MAbs; 2015; 7(1):199-211. PubMed ID: 25484043
[TBL] [Abstract][Full Text] [Related]
8. Epratuzumab for the treatment of systemic lupus erythematosus.
Geh D; Gordon C
Expert Rev Clin Immunol; 2018 Apr; 14(4):245-258. PubMed ID: 29542345
[TBL] [Abstract][Full Text] [Related]
9. Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model.
Wöhner M; Born S; Nitschke L
Eur J Immunol; 2012 Nov; 42(11):3009-18. PubMed ID: 22965838
[TBL] [Abstract][Full Text] [Related]
10. CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance.
Nitschke L
Glycobiology; 2014 Sep; 24(9):807-17. PubMed ID: 25002414
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.
Giltiay NV; Shu GL; Shock A; Clark EA
Arthritis Res Ther; 2017 May; 19(1):91. PubMed ID: 28506291
[TBL] [Abstract][Full Text] [Related]
12. Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model.
Bednar KJ; Shanina E; Ballet R; Connors EP; Duan S; Juan J; Arlian BM; Kulis MD; Butcher EC; Fung-Leung WP; Rao TS; Paulson JC; Macauley MS
J Immunol; 2017 Nov; 199(9):3116-3128. PubMed ID: 28972089
[TBL] [Abstract][Full Text] [Related]
13. [Recent Advances of Researches on Expression, Function and Regulation of CD22].
Wu XJ; Shao ZH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):573-7. PubMed ID: 25948227
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus.
Rao V; Gordon C
Immunotherapy; 2014; 6(11):1165-75. PubMed ID: 25496332
[TBL] [Abstract][Full Text] [Related]
15. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.
Steinfeld SD; Youinou P
Expert Opin Biol Ther; 2006 Sep; 6(9):943-9. PubMed ID: 16918261
[TBL] [Abstract][Full Text] [Related]
16. Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again.
Eisenberg R
Arthritis Res Ther; 2006; 8(3):108. PubMed ID: 16732895
[TBL] [Abstract][Full Text] [Related]
17. B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder.
Goldenberg DM; Stein R; Leonard JP; Steinfeld SD; Dörner T; Burmester GR
Arthritis Rheum; 2006 Jul; 54(7):2344; author reply 2344-5. PubMed ID: 16802381
[No Abstract] [Full Text] [Related]
18. CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity.
Clark EA; Giltiay NV
Front Immunol; 2018; 9():2235. PubMed ID: 30323814
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells.
Fleischer SJ; Daridon C; Fleischer V; Lipsky PE; Dörner T
Arthritis Rheumatol; 2016 May; 68(5):1210-21. PubMed ID: 26713408
[TBL] [Abstract][Full Text] [Related]
20. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.
Tedder TF; Poe JC; Haas KM
Adv Immunol; 2005; 88():1-50. PubMed ID: 16227086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]